• Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer
  • News
  • Contact
    • Directions

News

News Subscription

Apr 21. 2016
Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting
Read more
Download
Apr 20. 2016
Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
Read more
Download
Apr 15. 2016
Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Read more
Download
Mar 15. 2016
Basilea issues agenda for Annual General Meeting of Shareholders
Read more
Download
Mar 09. 2016
Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis
Read more
Download
Mar 04. 2016
Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
Read more
Download
Mar 03. 2016
Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
Read more
Download
Feb 29. 2016
Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
Read more
Download
Jan 22. 2016
GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program
Read more
Download
Dec 29. 2015
Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor
Read more
Download
  • previous
  • 1
  • …
  • 23
  • 24
  • 25
  • …
  • 32
  • next
  • Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer

Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland

P: +41 61 606 11 11
E-mail: info@basilea.com

News subscription
  • Imprint
  • Terms of use and Privacy Notice
  • EFPIA Disclosure Code
  • Expanded Access Policy
  • Transparence des liens d’intérêt

© 2026 Basilea Pharmaceutica Ltd, Allschwil